- Home
- QH vs EPRX Comparison
QH vs EPRX Comparison
Compare QH & EPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QH
- EPRX
- Stock Information
- Founded
- QH 2012
- EPRX 2011
- Country
- QH China
- EPRX Canada
- Employees
- QH N/A
- EPRX N/A
- Industry
- QH Business Services
- EPRX
- Sector
- QH Consumer Discretionary
- EPRX
- Exchange
- QH Nasdaq
- EPRX NYSE
- Market Cap
- QH 104.9M
- EPRX 137.7M
- IPO Year
- QH 2020
- EPRX N/A
- Fundamental
- Price
- QH N/A
- EPRX $5.39
- Analyst Decision
- QH
- EPRX Strong Buy
- Analyst Count
- QH 0
- EPRX 1
- Target Price
- QH N/A
- EPRX $12.00
- AVG Volume (30 Days)
- QH 10.5K
- EPRX 13.0K
- Earning Date
- QH 08-27-2025
- EPRX 08-07-2025
- Dividend Yield
- QH N/A
- EPRX N/A
- EPS Growth
- QH N/A
- EPRX N/A
- EPS
- QH 0.01
- EPRX N/A
- Revenue
- QH $417,431,053.00
- EPRX N/A
- Revenue This Year
- QH N/A
- EPRX N/A
- Revenue Next Year
- QH N/A
- EPRX N/A
- P/E Ratio
- QH $145.94
- EPRX N/A
- Revenue Growth
- QH N/A
- EPRX N/A
- 52 Week Low
- QH $0.25
- EPRX $2.20
- 52 Week High
- QH $2.27
- EPRX $6.20
- Technical
- Relative Strength Index (RSI)
- QH 60.41
- EPRX N/A
- Support Level
- QH $1.16
- EPRX N/A
- Resistance Level
- QH $1.30
- EPRX N/A
- Average True Range (ATR)
- QH 0.07
- EPRX 0.00
- MACD
- QH 0.02
- EPRX 0.00
- Stochastic Oscillator
- QH 57.75
- EPRX 0.00
About QH Quhuo Limited American Depository Shares
Quhuo Ltd is a gig economy platform focusing on local life services in China. It provide tech-enabled, end-to-end operational solutions to consumer service businesses, including on-demand delivery solutions, mobility service solutions, housekeeping and accommodation solutions, and other services. Its three operating segments, include (i) on-demand delivery solutions, (ii) mobility service solutions, and (iii) housekeeping and accommodation solutions and other services.
About EPRX EUPRAXIA PHARMACEUTICALS INC
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.